Click on headlines below to download research

KINETIC study discontinued
Kinarus Therapeutics | 03/10/2022

Kinarus recently reported H122 financial results and reiterated its key objectives and guidance for lead candidate KIN001 in the three targeted indications,…

H122 results reflect continued progress
Kinarus Therapeutics | 05/09/2022

Kinarus recently reported H122 financial results and reiterated its key objectives and guidance for lead candidate KIN001 in the three targeted indications,…

Phase II COVID-19 outpatient study underway
Kinarus Therapeutics | 31/08/2022

Kinarus has announced that it has dosed the first patient in its Phase II KINFAST study evaluating lead candidate KIN001 in mild or moderate COVID-19 patients…